A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC 703813, IND70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Trial Profile

A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC 703813, IND70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms Alliance; CALGB 50803
  • Most Recent Events

    • 31 Aug 2017 Primary endpoint (Number of Participants Who Achieved a Complete Response) has been met, according to the results published in the Annals of Oncology
    • 31 Aug 2017 Results published in the Annals of Oncology
    • 06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00117975 and NCT00553501) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top